ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety & Efficacy Study of EGF Cancer Vaccine to Treat Stage IV Biomarker Positive, Wild Type EGF-R NSCLC Patients (EGF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02187367
Recruitment Status : Recruiting
First Posted : July 11, 2014
Last Update Posted : July 18, 2017
Sponsor:
Information provided by (Responsible Party):
Bioven Sdn. Bhd. ( Bioven Europe )

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : February 2020
  Estimated Study Completion Date : March 2020